Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

Table 2 Overall change from baseline in MIDAS total score, headache days, headache pain, and number of treated attacks for patients who completed all 4 quarters of treatment

		Lasmiditan 100 mg (n = 974)		Lasmiditan 200 mg (n = 1063)
		Change from BL*		Change from BL*
		LS mean	% change in LS mean	LS mean	% change in LS mean
MIDAS Total Score	BL, mean^a	29.4		28.9
	Month 3	−7.7	−26.3	− 7.0	−24.3
	Month 6	−9.8	− 33.5	− 9.2	− 31.9
	Month 9	− 11.0	− 37.6	− 10.1	− 34.9
	Month 12	−12.5	− 42.6	− 12.2	− 42.2
Headache Days, past 3 months^{b, c}	BL, mean	15.5		15.5
	Month 3	−3.5	− 22.6	− 3.9	− 24.8
	Month 6	−4.5	−28.7	− 4.1	− 26.1
	Month 9	−5.2	− 33.7	− 5.7	− 36.7
	Month 12	−5.7	− 36.8	−6.0	−38.8
Average headache pain intensity^{b, d}	BL, mean	7.4		7.3
	Month 3	−0.4	−5.4	− 0.4	− 5.7
	Month 6	−0.7	−9.1	− 0.7	−9.0
	Month 9	−0.8	−10.4	−0.9	−11.9
	Month 12	−1.1	− 15.1	− 1.2	− 16.6
Number of treated attacks, past 3 months^e		Lasmiditan 100 mg		Lasmiditan 200 mg
		N	Mean	N	Mean
	Month 3	326	6.0	320	6.0
	Q2	312	5.0	296	4.9
	Q3	303	4.4	298	4.3
	Q4	336	3.7**	331	3.4**

Abbreviations: BL baseline; LS mean = least squares mean
^aBaseline n = 972 for lasmiditan 100 mg. ^bNot included in MIDAS total score. ^c“On how many days in the past 3 months did you have a headache? (If a headache lasted more than 1 day, count each day)” ^dScale 1–10. ^eData shown for patients who completed all 4 quarters. *All changes from baseline significant at p < 0.001. **p-values from paired t-tests vs 1st quarter

ISSN: 1129-2377